Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis
- 41 Downloads
Objective and Design: A novel immunomodulating drug, leflunomide has been shown recently to be effective and well tolerated in patients suffering from rheumatoid arthritis (RA). The present study evaluated the effect of the drug on cell adhesion in RA.
Material and Treatment: Peripheral blood and synovial fluid mononuclear cells were obtained from a clinical trial, undertaken primarily to evaluate the efficacy and pharmacokinetic profile of multiple-dose pulsing leflunomide therapy in RA patients. PB MNC and corresponding synovial fluid (SF) MNC for in vitro homotypic aggregation (HA) assay were obtained from healthy volunteers and RA patients with active disease not treated with leflunomide in vivo.
Methods: Expression of activation antigens (CD25, CD54, CD69, CD71, HLA-DR) on peripheral blood mononuclear cells (PB MNC), as well as ex vivo ability of cells to aggregate spontaneously were determined in patients before entering into the clinical trial and at the end of 6 months treatment. HA was measured by aggregation in vitro. Data were compared by Student's t-test.
Results: There was a decreased expression of activation antigens and decreased spontaneous MNC clustering after leflunomide therapy. We found in the in vitro study that HA of PB and SF MNC was mainly mediated through β2-integrin molecules. The active metabolite of leflunomide, A77 1726, effectively suppressed both spontaneous and phorbol-ester (PMA)-induced HA. Disruption of cell aggregates by A77 1726 was dose-dependent and, most likely, unrelated to the quantitative modulation of integrin receptors.
Conclusions: Results from this study support the idea that leflunomide elicits its immunomodulatory action, at least partially, by modulating the adhesion process.
Key wordsLeflunomide Homotypic adhesion Rheumatoid arthritis
Unable to display preview. Download preview PDF.
- Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivate, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharm 1985;7:7–18.Google Scholar
- Smith-Long L, Glaser B, Weimer LK, Miller ST, Robertson SM, Aoki KR, et al. Efficacy of novel immunomodulators leflunomide and rapamycin in autoimmune uveitis. FASEB J 1992;6:A1048.Google Scholar
- Xiao F, Chong AS-F, Bartlett RR, Williams JW, Leflunomide: a promising immunosuppressant in transplantation. In: Thompson AW, Starzl TE, editors. Immunosuppressive Drugs. Developments in anti-rejection therapy. London: Edward Arnold, 1994;203–12.Google Scholar
- Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic, D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomised, placebo-controlled, phase II study. Arthr Rheum 1995;38:1595–603.Google Scholar
- Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R. Effects of leflunomide on immune responses and models of inflammation. Springer Sem Immunopathol 1993;14:381–94.Google Scholar
- Bartlett RR, Zielinski T, Campion G, Musikic P, Schleyerbach R, Schorlemmer H-U. Chapter 20: Leflunomide: A novel immunomodulatory drug. In: Lewis AJ, Furst D, editors. Non-Steroidal Anti-Inflammatory Drugs II. New York: Marcel Dekker, 1994:349–66.Google Scholar
- Zielinski T, Muller HJ, Schleyerbach R, Bartlett RR. Differential effects of leflunomide on leukocytes: inhibition of rat in vivo adhesion and in vitro oxidative burst without affecting surface marker modulation. Agents Actions 1994;41:C276–8.Google Scholar
- Zielinski T, Zeitter D, Mullner S, Bartlett RR. Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? Inflamm Res 1995;44 Suppl 2:S207–8.Google Scholar
- Haynes BF, Hale LP, Patton KL, Martin ME, McCallum RM. Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Arthr Rheum 1991;34:1434–43.Google Scholar
- Oppenheimer-Marks N, Lipsky PE. The role of cell adhesion in the evolution of inflammatory arthritis. In: Wegner CD, editor. Adhesive Molecules. London: Academic Press, 1994: 141–61.Google Scholar
- van Seventer GA, Newman W, Shimizu Y, Nutman TB, Tanaka Y, Horgan KJ, et al. Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: co-stimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. J Exp Med 1991;174:901–13.PubMedGoogle Scholar
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988;31:315–24.Google Scholar
- Hovendes J, Gaudernack G, Kvien TK, Egeland T. Expression of activation markers on CD4+ and CD8+ cells from synovial fluid, synovial tissue and peripheral blood of patients with inflammatory arthritides. Scand J Immunol 1989;29: 631–9.Google Scholar
- Sanders ME, Makgoba WM, Sharrow SO, Stephany D, Springer TA, Young HA, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2 and LFA-1) and three other molecules (UCHL 1, CDw29 and Ppg-1) and have enhanced IFN-γ production. J Immunol 1988;140:1401–7.PubMedGoogle Scholar
- Locey BJ, Rogers CM, Todd RF. The role of CD11/CD18 integrin molecules in neutrophil and monocyte homotypic adhesion. In: Knapp W, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK, editors. Leukocyte Typing IV. White Cell Differentiation Antigens. Oxford: Oxford University Press, 1989:555–8.Google Scholar
- Pavlovic MD, Colic M, Pejnovic N, Tamatani T, Miyasaka M, Dujic A. A novel anti-rat CD18 monoclonal antibody triggers lymphocyte homotypic aggregation and granulocyte adhesion to plastic: different intracellular signaling pathways in resting versus activated thymocytes. Eur J Immunol 1994;24: 1640–8.PubMedGoogle Scholar
- Hibbs ML, Xu H, Stocker SA, Springer TA. Regulation of adhesion to ICAM-1 by the cytoplasmic domain of LFA-1 integrin beta subunit. Science 1991;251:1537–42.Google Scholar
- Pals ST. CD44, a family of molecules involved in lymphocyte activation and inflammation. Rheumatol in Europe 1995;24: 35–7.Google Scholar